peptide
Tirzepatide
strongFDA-Approved· RxInjection
Active ingredient in Mounjaro/Zepbound. Dual GLP-1/GIP agonist — more effective than semaglutide. SURMOUNT-1 showed up to 22.5% weight loss at 72 weeks.
Key facts
- Classification
- Tirzepatide is a dual GIP/GLP-1 receptor agonist with C-20 fatty diacid for weekly dosing.
- Primary benefits
- Fat Loss (10/10) · Longevity (5/10) · Gut Health (3/10)
- Administration
- Injection
- Doses studied
- Start at 2.5 mg per week and gradually increase to 5-15 mg per week. Meant for long-term use.
- Evidence strength
- Strong — 21 peer-reviewed studies
- Stacks well with
- 5-Amino-1MQ, MOTS-c, BPC-157
- Legal status
- FDA-Approved · prescription required · WADA prohibited
Quick stats
- Type
- Peptide
- Administration
- Injection
- Studies referenced
- 21
- Stacks with
- 3 peptides
- Regulatory
- FDA-Approved
Scientific overview
Tirzepatide is a dual GIP/GLP-1 receptor agonist with C-20 fatty diacid for weekly dosing. SURMOUNT-1 showed up to 22.5% weight reduction at 72 weeks. Dual incretin mechanism produces greater insulin sensitization than GLP-1-only agonists, with additional effects on lipid metabolism and hepatic steatosis.
Goal coverage · Tirzepatide
🔥 Fat Loss10/10
⏳ Longevity5/10
🫃 Gut Health3/10
🧊 Inflammation3/10
Medical oversight requiredNot safe during pregnancy· 5 contraindications